viernes, 29 de diciembre de 2023

Lisocabtagene maraleucel: A cost-effective second-line treatment for relapsed/refractory DLBCL

https://www.news-medical.net/news/20231228/Lisocabtagene-maraleucel-A-cost-effective-second-line-treatment-for-relapsedrefractory-DLBCL.aspx

No hay comentarios:

Publicar un comentario